Medical network, June 20, I stood in the 2017 today, review some industry predicted last year, such as "medicine group of large-scale disappear" "2017 corporate mergers and acquisitions more violent," found that were dashed.
As of the end of November 2016, there were 12,975 wholesale pharmaceutical enterprises nationwide, according to a report released by the ministry of commerce on June 14, 2016. Compared with 2015, the number of drug approvals in 2016 disappeared by 533 -- a far cry from the "massive".
As for "the merger of drug companies in 2017", which was compiled this year by cypress blue, there are only eight acquisitions. Although it is inevitable that there will be no such thing, there is no such thing as a "heavy" takeover.
These "big small" acquisition case is normal commercial law, if be summed up a wind direction, can say big branch will be more and more, increasing resource integration ability. But that is not to be surprising, as is the case in every industry.
In fact, the pharmaceutical industry long-term addicted to study policies, and disconnect and the free market economy already a long time, for the coming a few enterprise control most of the market of the era of "oligarchs" panic, on the one hand is the lack of foresight; The other is the unclueless weakness of the policy attachment.
Even if there is a big business, there is no medicine to eliminate the meaning of small and medium enterprises. "Developing characteristic management" is the government's advice to small and medium-sized enterprises. If you don't know what a feature is, you can understand it as a differentiating business. Refer to "jd.com" to "taobao"; "Coca-Cola" is Pepsi.
Back to the topic of prophecy, there are many illusions about the future. Big price rises, big price cuts, big changes, too hard to survive, too hard and so on. Simply put together the information that will be collected in the media and corporate announcements.
The company bought two Italian companies for $837 million
Fairy Ju pharmaceutical late on June 19, 2017 announcement, the company offered 110 million euros (RMB 837.33 million) to buy Italian Newchem S.P.A. and Effechem S.R.L. 100% stake. Newchem company was founded in 1998, mainly engaged in active pharmaceutical ingredients, mainly steroid and hormone drugs research and development, production, sales, and in agriculture, food, environmental protection, the beauty industry, physical therapy industry application research. Effechem was founded in 1975 and is mainly engaged in various sales activities in the pharmaceutical industry.
Bayda pharmaceuticals has bought the drug for $500m
On June 19, 2017, beida pharmaceutical announcement, announced in its own funds 108.43 million yuan public delisting acquisitions of two companies respectively hold CARDS were 13.5% and 9.09% stake in southern kyrgyzstan. As early as February 2017, beida was able to receive 77.41 per cent of its existing shareholders in the form of 372 million yuan (tax) cash.
So far, the company has invested nearly 500 million yuan in 100 percent of the company. Kananji pharma is an anti-cancer drug discovery company.
Shaanxi will be bought by shaanxi province
On June 16, will share announcement, agree that the company is a wholly owned subsidiary of shaanxi will kang pharmaceutical group holding co., LTD purchase shenze quiet creek pharmaceutical technology co., LTD. Held by hebei embellish auspicious pharmaceutical co., LTD. 70% stake. On June 14, 2017, hebei runxiang completed the shareholding change.
After this change, shaanxi will hold 70 percent of hebei resources, and hebei runxiang will become the subsidiary of shaanxi province.
Seisheng pharmaceuticals 4 billion, sold to the Chinese consortium
The raw pharmaceutical announced June 8, have accepted by telford capital, bank of China group investment co., LTD., CDH investments, it reaches to the capital, bo and other five Chinese win vc investment agencies jointly launched a $605 million (4 billion yuan).
The raw pharmaceutical based in foster city in the United States, but the actual business in China, the main products mainly covers the tumor, infectious disease and cardiovascular disease, monopoly product of fairy new method (thymus) went public in 1996.
Chinese medicine bought kangli pharmaceutical for 280 million
Chinese medicine announced on June 7 that the company intends to buy a 54 percent stake in hainan general kangli pharmaceutical co., LTD., with a total of 28,620 million yuan. After the completion of this transaction, conforce will be incorporated into the China medical consolidated report.
It is understood that the main varieties of hainan kangli are piperazilin, propionyl glutamine, etc. In the production in sales more than 50 products rules, give priority to with producing injection, sterile powder injection, antibiotics, drugs, cardiovascular drugs, and other areas of the main nutrition.
Kepeople is a credible acquisition of jiuhua pharmaceutical
In April 2017, ji people's trust group merged with jiangxihua pharmaceutical co., LTD.
The company was established in 1969, and was approved by the foreign economic and trade department of jiangxi province in December 2006 and changed its name to jiangxihua pharmaceutical co., LTD. It is a high-tech enterprise which is mainly manufactured in China. The main products of the company include: jiuhua hemorrhoids, cordyceps, the lumbar pain pill, the combination of the antipyretic and the rheumatoid pain medicine, etc.
Hong and pharmaceuticals (China)
On March 22, 2017, sihuan pharmaceutical announced that the company's wholly-owned subsidiary yao zhong international (Hong Kong) co., LTD. And hong and pharmaceutical group co., LTD., conclude a share purchase agreement, to 1.1 billion yuan price to buy its holding wong and pharmaceutical (China) co., LTD. 100% stake. After the acquisition, hong and pharmaceutical (China) will become a wholly owned subsidiary of the group.
Hong and pharmaceutical (China) are engaged in the research, technology transfer and technical services of large-capacity injection production and pharmaceuticals; Currently, the production approval of the drug includes the injection of ammonium glycysteine, the injection of sodium cysteine chloride, and the injection of legume.
China resources sanjiu bought jilin province
On January 17, 2017, huarun sanjiu signed a cooperation ceremony with jilin jinlin pharmaceutical industry. China resources sanjiu bought a 65 per cent stake in jilin jinlin pharmaceutical co., LTD., which is owned by jilin donglang pharmaceutical co., LTD.
Founded in July 2011, jilin compound pharmaceutical co., LTD. Has two exclusive products, including the probiotics capsule, and the gold compound oral liquid. |
